Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Name of entity

IM Medical Limited ("Company")

ABN

3

47 009 436 908

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- 1 *Class of *securities issued or to be issued
- 2 Number of *securities issued or to be issued (if known) or maximum number which may be issued

Principal terms of the +securities (eg, if

options, exercise price and expiry date; if partly paid ⁺securities, the amount

outstanding and due dates for payment;

if ⁺convertible securities, the conversion price and dates for conversion)

Fully paid ordinary shares and free attaching options.

498,237,396 fully paid ordinary shares.

498,237,396 free attaching options.

Fully paid ordinary shares

Free attaching options (each with an exercise price of \$0.002 expiring or before 31 March 2019)

⁺ See chapter 19 for defined terms.

4	Do the ⁺ securities rank equally in all respects from the date of allotment with an existing ⁺ class of quoted ⁺ securities?	Shares will rank equally ordinary shares.	/ with existing fully paid					
	 If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	Free attaching options of existing listed IMIOA op exercise of the options equally with existing sh	otions. Shares issued on to shares will rank					
F	lacus suise or consideration							
5	Issue price or consideration	\$0.001 cents per Share. Options free attaching						
			subscribed for under the					
		offer.	subscribed for under the					
		offer.						
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Non-renounceable pro-rata offer to eligible shareholders as at the record date. Funds raised will be used for the payment of liabilities and existing creditors and to provide working capital.						
7	Dates of entering ⁺ securities into uncertificated holdings or despatch of certificates	12 May 2017						
0		Number	+Class					
8	Number and ⁺ class of all ⁺ securities quoted on ASX (<i>including</i> the securities in clause 2 if applicable)	1,826,870,453	Fully paid ordinary shares.					
		993,302,151	Options exercisable at					
			\$0.002 on or before					
			31 March 2019.					

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and ⁺ class of all ⁺ securities not quoted on ASX (<i>including</i> the securities in clause 2 if applicable)		

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No change.

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non-	non-renounceable
	renounceable?	
13	Ratio in which the ⁺ securities will be offered	3 Shares for every 8 Shares held. 1 free attaching option for each new share subscribed for under the offer.
14	⁺ Class of ⁺ securities to which the offer relates	Fully paid ordinary shares. Free attaching options (each with an exercise price of \$0.002 expiring or before 31 March 2019).
15	⁺ Record date to determine entitlements	10 April 2017

⁺ See chapter 19 for defined terms.

16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	Yes
17	Policy for deciding entitlements in relation to fractions	Rounded down
18	Names of countries in which the entity has ⁺ security holders who will not be sent new issue documents	All countries other than Australia and New Zealand
	Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	5 May 2017
20	Names of any underwriters	Patersons Securities Limited
21	Amount of any underwriting fee or commission	6.50% on the total amount raised under the offer
22	Names of any brokers to the issue	Patersons Securities Limited
23	Fee or commission payable to the broker to the issue	Nil
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of ⁺ security holders	Nil
25	If the issue is contingent on *security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled	13 April 2017
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	13 April 2017
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if	N/A

⁺ See chapter 19 for defined terms.

	applicable)	
30	How do ⁺ security holders sell their entitlements <i>in full</i> through a broker?	N/A
31	How do ⁺ security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do ⁺ security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	⁺ Issue date	12 May 2017

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

34	Type o (<i>tick or</i>	f securities ////////////////////////////////////
(a)		Securities described in Part 1
(b)		All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001 and over
37	A copy of any trust deed for the additional +securities

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

- 38 Number of securities for which ⁺quotation is sought
- 39 Class of ⁺securities for which quotation is sought
- 40 Do the ⁺securities rank equally in all respects from the date of allotment with an existing ⁺class of quoted ⁺securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment


41 Reason for request for quotation now

Example: In the case of restricted securities, end of restriction period $% \left[{{\left[{{{\left[{{{c}} \right]}} \right]_{{\rm{c}}}}_{{\rm{c}}}}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{\left[{{{{c}}} \right]_{{\rm{c}}}}_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{\left[{{{{c}}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{{c}}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}}}} \right]_{{\rm{c}}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}}} \right]_{{\rm{c}}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}}} \left[{{\left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}}}} \right]_{{\rm{c}}}}} \left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}} \left[{{{c}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}} \left[{{{c}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{\rm{c}}}} \left[{{{c}} \right]_{{$

(if issued upon conversion of another security, clearly identify that other security)

42 Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in clause 38)

Number	+Class	



⁺ See chapter 19 for defined terms.

Quotation agreement

- ¹ ⁺Quotation of our additional ⁺securities is in ASX's absolute discretion. ASX may quote the ⁺securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those 'securities should not be granted 'quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that noone has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before ⁺quotation of the ⁺securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

== == == == ==

(Director/Company secretary)

Date: 12 May 2017

Sign here:

Print name:

Richard Wadley

⁺ See chapter 19 for defined terms.

IM MEDICAL LTD FULLY PAID Top 20 Listing



			Current Date - 12/05/2017 Time - 8 10 26	e - 8 10 26	Preview * Ac at	Previous Top * As at: 12/05/17 *	
Rank	k Holder Name	Designation	Current Securities	%	Prev. Securities	%	Rank
н	CHESAPEAKE CAP I		196,069,080	10.73%			
* 2	BAHEN MARK JOHN + M P	SUPER ACCOUNT	127,470,237	6.98%	127,470,237	8.06%	1
m	BEIRNE TRADING PL		63,879,831	3.50%	63,879,831	4.04%	2
* 4	BROWN BRICKS PL	HM A/C	56,354,629	3.08%	56,354,629	3.56%	m
ъ	G & N LORD SUPER PL	GNR SUPER FUND A/C	55,609,091	3.04%	55,609,091	3.52%	4
9	PATERSONS SEC LTD	CORP FINANCE A/C	55,141,188	3.02%	55,141,188	3.49%	ß
7	FERNLAND HLDGS PL	CELATO A/C	52,078,676	2.85%	2,078,676	0.13%	107
8	TWO TOPS PL		51,218,750	2.80%	51,218,750	3.24%	9
۰ ۴	T T NICHOLLS PL	SUPER ACCOUNT	49,317,507	2.70%	49,317,507	3.12%	7
10	KIRZY PL	SPRINGDALE NO 2 A/	40,000,009	2.19%	40,000,009	2.53%	8
11	SKYE EQUITY PL		40,000,000	2.19%	40,000,000	2.53%	6
* 12	ALDERHAUS PL		37,643,549	2.06%	37,643,549	2.38%	10
13	SAM GOULOPOULOS PL	S GOULOPOULOS F/SU	35,000,000	1.92%	35,000,000	2.21%	11
14	REDCLIFF PL	MCGHEE S/F A/C	33,227,273	1.82%	33,227,273	2.10%	12
15	HOPPSCOTCH PL	HOPSCOTCH S/F A/C	31,095,852	1.70%	31,095,852	1.97%	13
16	KOBIA HLDGS PL		25,781,250	1.41%	25,781,250	1.63%	14
* 17	JASPER HILL RES PL	SUPER ACCOUNT	25,326,834	1.39%	25,326,834	1.60%	15
18		MG FAM A/C	22,500,000	1.23%	22,500,000	1.42%	16
19	RETZOS INV PL	RETZOS ALTONA PROP	22,500,000	1.23%	22,500,000	1.42%	17
20	LOQUELA PL		20,000,018	1.09%	20,000,018	1.27%	18
		TOP 20 TOTAL	1,040,213,774	56.93%	794,144,694	50.22%	
	* Denotes merged holders. Note: All holders are included in the remote						
	ואחרבי אוו ווחומבוא מוב ווורוממבמ ווו הוב ובלחורי						

Page 1 of 1



IM MEDICAL LTD FULLY PAID Spread Analysis Date - 12/05/2017 Time - 8.10.26

Spread of Holdin	gs Holders	Securities	% of Issued Capital		
NIL hold	-		0.00%		
	00 2,615		0.05%		
1,001 - 5,	00 1,133	2,978,621	0.16%		
5,001 - 10,	00 354	2,830,633	0.15%		
10,001 - 100,	00 438	13,702,830	0.75%		
Over 100,	00 332	1,806,472,736	98.88%		
TOTAL ON REGIS	ER 4,872	1,826,870,453			
Analysis by Loca	on				
Overs	eas 98	26,594,660	1.46%		
Austra	ia: 4,184	1,794,332,032	98.22%		
	CT 51	700,334	0.04%		
N	SW 961		8.20%		
	/IC 1,553	310,599,111	17.00%		
(LD 521	47,613,704	2.61%		
	SA 366	17,990,985	0.98%		
	VA 625		69.22%		
· · ·	AS 86		0.16%		
	NT 21	285,646	0.02%		
Address Unkno		,	0.33%		
	550	5,515,701	0.5570		
TOTAL ON REGIST	ER 4,872	1,826,870,453			
		2,020,070,100			

Note: All holders are included in the report, with common holders merged into one holding.

IS EXP 31/03/2019 @ \$0.002	
\$0.	
0	
19	
/20	
(03	
31/	ing
EXP	List
NS	20 L
P E	do
I MEDICAL LTD OPTION	F
ē	
÷	
GAL	
Ĩ	
Σ	
Σ	
•••	



I

(

(

		Rank		-	91	2	ო	4	S	9	7	8	6	10	11	12	13	14	15	16	17	18			
	7 *			8.54%	0.08%	6.40%	5.76%	5.49%	4.30%	4.10%	4.00%	3.88%	3.00%	2.80%	2.64%	2.51%	2.37%	2.28%	2.25%	1.76%	1.71%	1.55%	65.42%		
Previous Top	* As at: 12/05/17 *	%																							
Pre	* As a	curities		63,790,182	566,911	47,842,636	43,007,047	41,014,610	32,152,273	30,663,644	29,909,091	28,959,604	22,431,818	20,947,546	19,704,545	18,750,000	17,718,750	17,031,250	16,838,654	13,136,364	12,750,000	11,565,554	488,780,479		
		Prev. Securities		63,		47,	43,	41,	32,	30,	29,	28,	22,	20,	19,	18,	17,	17,	16,	13,	12,	11,	488,		
	1.56		19.74%	6.42%	5.09%	4.82%	4.33%	4.13%	3.24%	3.09%	3.01%	2.92%	2.26%	2.11%	1.98%	1.89%	1.78%	1.71%	1.70%	1.32%	1.28%	1.16%	73.98%		
It	Time - 8.1	%																							
Current	Date - 12/05/2017 Time - 8.11.56	curities	196,069,080	63,790,182	50,566,911	47,842,636	43,007,047	41,014,610	32,152,273	30,663,644	29,909,091	28,959,604	22,431,818	20,947,546	19,704,545	18,750,000	17,718,750	17,031,250	16,838,654	13,136,364	12,750,000	11,565,554	734,849,559		
	Date - 12,	Current Securities	196	63	20	47	43	41	32	30	29	28	22	20	19	18	17	17	16	13	12	11	734		
		0																							
		ion																							
		Designation				FUND A/	JNT	JNT	UND A/C	NO 2 A/			A/C			RADING					I A/C	S/F A/C	Ł		
					CELATO A/C	TROJAN CAP FUND A	SUPER ACCOUNT	SUPER ACCOUNT	GNR SUPER FUND A/C	SPRINGDALE NO	HM A/C		MCGHEE S/F A/C			XCELERATE TRADING					JANE KIDMAN A/C	HOPSCOTCH S/F	TOP 20 TOTAL		
					GEI	TR(SUF	SUF	GN	SPF	MΗ		МQ			XCE					JAN	ЮH	10		
																								-	report.
		Holder Name						д							<u>ب</u>						Н				ded in the
		Holde	AP LTD	NG PL	JGS PL	CE PL	РL	M + NHO	JPER PL		S PL			ROBERT	DTTAGES I	ADING PL		۲		DING CO PI	CHRISTABI	۲		ged holder:	's are inciu
			CHESAPEAKE CAP LTD	BEIRNE TRADING PL	FERNLAND HLDGS PL	ROCKET SCIENCE PL	L T NICHOLLS PL	BAHEN MARK JOHN + M P	G & N LORD SUPER PL	Y PL	BROWN BRICKS PL	ALDERHAUS PL	REDCLIFF PL	EVANS SIMON ROBERT	WALLCLIFFE COTTAGES PL	XCELERATE TRADING PL	TWO TOPS PL	KOBIA HLDGS PL	LOQUELA PL	HOWARD TRADING CO PL	KIDMAN JANE CHRISTABEL	HOPPSCOTCH PL		* Denotes merged holders.	Note: All holders are included in the report.
		Rank	1 CHES	2 BEIR	3 FERN	4 ROC	5 TTN	6 BAHE	7 G&F	8 KIRZY PL	9 BROV	10 ALDE	11 REDC	12 EVAN	13 WALL	14 XCEL	15 TWO	16 KOBI	17 LOQL	18 HOW	19 KIDM	20 HOPP		* Dei	NOTE.
		R				*	*	*			*	*													

Page 1 of 1



IM MEDICAL LTD OPTIONS EXP 31/03/2019 @ \$0.002 Spread Analysis Date - 12/05/2017 Time - 8.11.56

Spread of Holdings	Holders	Securities	% of Issued Capital
NIL holding	0	0	0.00%
1 - 1,000	19	17,030	0.00%
1,001 - 5,000	39	109,262	0.01%
5,001 - 10,000	14	107,744	0.01%
10,001 - 100,000	39	1,887,134	0.19%
Over 100,000	136	991,180,981	99.79%
TOTAL ON REGISTER	247	993,302,151	
Analysis by Location			
Overseas	3	9,684,190	0.97%
Australia:	244	983,617,961	99.03%
ACT	1	10,000	0.00%
NSW	50	94,538,214	9.52%
VIC	66	154,059,808	15.51%
QLD	33	61,561,125	6.20%
SA	17	8,489,764	0.85%
WA	71	664,610,996	66.91%
TAS	6	348,054	0.04%
NT	0	0	0.00%
Address Unknown	0	0	0.00%
TOTAL ON REGISTER	247	993,302,151	

Note: All holders are included in the report, with common holders merged into one holding.